Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 485-35-8 Chemical Structure| 485-35-8

Structure of Cytisinicline
CAS No.: 485-35-8

Chemical Structure| 485-35-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cytisine is a naturally occuring alkaloid nAchR agonist with a short half-life of 4.8 hours.

Synonyms: Cytisine; Sophorine; Sophorin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cytisinicline

CAS No. :485-35-8
Formula : C11H14N2O
M.W : 190.24
SMILES Code : O=C1/C=C\C=C2/N1C[C@@H]3CNC[C@H]2C3
Synonyms :
Cytisine; Sophorine; Sophorin
MDL No. :MFCD00136048

Safety of Cytisinicline

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H311-H331
Precautionary Statements:P261-P264-P270-P271-P280-P302+P352-P304+P340-P310-P330-P361-P403+P233-P405-P501
Class:6.1
UN#:1544
Packing Group:

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03654105 Inflammation ... More >>Smoking Cessation Diet Modification Physical Activity Lung Cancer Less << Phase 2 Not yet recruiting October 2020 Italy ... More >> Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy, 20133 Less <<
NCT02797587 HIV Infection ... More >> Alcohol Use Smoking Less << Phase 2 Phase 3 Recruiting December 2020 Russian Federation ... More >> First St. Petersburg Pavlov State Medical University Recruiting St. Petersburg, Russian Federation, 197022 Contact: Evgeny Krupitsky, MD,PhD,DMdSc    +7-812-365-2217    kruenator@gmail.com Less <<
NCT03709823 Smoking Cessation Phase 2 Recruiting June 30, 2019 United States, Arizona ... More >> Clinical Research Consortium Recruiting Tempe, Arizona, United States, 85283 Contact: Corey G Anderson, MD          United States, California Los Angeles Clinical Trials Recruiting Burbank, California, United States, 91505 Contact: Nitchell Nides, PhD          United States, Kentucky Central Kentucky Research Associates, LLC Recruiting Lexington, Kentucky, United States, 40509 Contact: Mark S Adams, MD          United States, Missouri Center for Pharmaceutical Research, LLC Recruiting Kansas City, Missouri, United States, 64114 Contact: John E Ervin, MD          United States, New York Rochester Clinical Research, Inc Recruiting Rochester, New York, United States, 14609 Contact: Matthew G Davis, MD          United States, South Carolina Coastal Carolina Research Center, Inc Recruiting Mount Pleasant, South Carolina, United States, 29464 Contact: Cynthia Strout, MD          United States, Tennessee Volunteer Research Group Recruiting Knoxville, Tennessee, United States, 37920 Contact: William B Smith, MD          United States, Texas FutureSearch Trails of Dallas, LP Recruiting Dallas, Texas, United States, 57231 Contact: Michael Downing, MD Less <<
NCT02957786 Smoking Cessation Phase 3 Recruiting May 2019 New Zealand ... More >> National Institute for Health Innovation, University of Auckland Recruiting Auckland, North Island, New Zealand, 1072 Contact: Natalie Walker, PhD    64 9 373 7999    n.walker@auckland.ac.nz    Contact: Chris Bullen, PhD, MBChB    64 9 373 7999    c.bullen@auckland.ac.nz    Principal Investigator: Natalie Walker, PhD          Sub-Investigator: Chris Bullen, PhD;MBChB          Sub-Investigator: Joanne Barnes, PhD          Sub-Investigator: Barry Smith, PhD          Sub-Investigator: Subhash Pokhrel, PhD          Sub-Investigator: Varsha Parag, MSc (Hons) Less <<
NCT03268343 Smoking Cessation PHASE1 COMPLETED 2017-09-01 Simbec Research Ltd, Merthyr T... More >>ydfil, CF11 9AB, United Kingdom Less <<
NCT02585024 Smoking Cessation PHASE1 TERMINATED 2025-03-19 Soo Hee Jeong, Auckland, 1072,... More >> New Zealand Less <<
NCT03303911 Smoking Cessation PHASE1|PHASE2 TERMINATED 2018-10-05 Simbec Research Ltd, Cardiff, ... More >>CF11 9AB, United Kingdom Less <<
NCT03509948 Smoking Cessation Phase 1 Completed - United Kingdom ... More >> Simbec Research Ltd Cardiff, United Kingdom, CF11 9AB Less <<
NCT06435221 Smoking Cessation|Vaping Cessa... More >>tion Less << PHASE3 ACTIVE_NOT_RECRUITING 2025-12-31 Alliance for Multispecialty Re... More >>search, LLC, Mobile, Alabama, 36608, United States|Alliance for Multispecialty Research, LLC, Tempe, Arizona, 85281, United States|Little Rock Allergy & Asthma Clinical Research Center, Little Rock, Arkansas, 72205, United States|Alliance for Multispecialty Research, LLC, Coral Gables, Florida, 33134, United States|Accel Research Sites Network - DeLand Clinical Research Unit, DeLand, Florida, 32720, United States|Alliance for Multispecialty Research, LLC, Fort Myers, Florida, 33912, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, 32216, United States|Precision Clinical Research, Sunrise, Florida, 33351, United States|Clinical Research Atlanta, Stockbridge, Georgia, 30281, United States|Alliance for Multispecialty Research, LLC, Oak Brook, Illinois, 60523, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, 47714, United States|Alliance for Multispecialty Research, LLC, Wichita, Kansas, 67207, United States|Alliance for Multispecialty Research, LLC, Lexington, Kentucky, 40509, United States|Alliance for Multispecialty Research, LLC, New Orleans, Louisiana, 70119, United States|Massachusetts General Hospital - Clinical Genetic Facility, Boston, Massachusetts, 02114, United States|Insight Research Institute, Flint, Michigan, 48507, United States|Alliance for Multispecialty Research, LLC, Kansas City, Missouri, 64114, United States|Alliance for Multispecialty Research, LLC, Las Vegas, Nevada, 89119, United States|Global Medical Institutes LLC; Princeton Medical Institute, Princeton, New Jersey, 08540, United States|Rochester Clinical Research, LLC, Rochester, New York, 14609, United States|Centricity Research Columbus Ohio Multispecialty, Columbus, Ohio, 43213, United States|Alliance for Multispecialty Research, LLC, Norman, Oklahoma, 73069, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, 16635, United States|Coastal Carolina Research Center, North Charleston, South Carolina, 29405, United States|Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, 37909, United States|Clinical Research Associates, Inc., Nashville, Tennessee, 37203, United States|Clinical Trials of Texas, LLC, San Antonio, Texas, 78229, United States|Health Research of Hampton Roads, Inc., Newport News, Virginia, 23606, United States|Alliance for Multispecialty Research, LLC, Norfolk, Virginia, 23502, United States Less <<
NCT05981768 Smoking Cessation PHASE1 COMPLETED 2023-09-21 BlueClinical Phase I, Porto, 4... More >>250-449, Portugal Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.26mL

1.05mL

0.53mL

26.28mL

5.26mL

2.63mL

52.57mL

10.51mL

5.26mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories